Dr. Jingping Yun is currently a Professor of Pathology at Sun Yat-sen University Cancer Center. He served as the Director of Pathology Department in SYSUCC since 2010. He specializes in the pathological diagnosis of tumor for nearly 30 years. Dr. Yun had been further educated in Prince of Wales Hospital in 1997. He currently serves as Vice Chairman in the pathologists committee of CSCO and the Pathology Branch of Guangdong Medical Doctor Association. He is also the chairman-elected of the pathologists committee of Guangdong Anti-cancer Association. Dr. Yun is known for his academic contributions to molecular mechanism in liver cancer development, as well as the  prognostic, predictive, and diagnostic markers for GI tumors. He has authored or co-authored over 90 peer-reviewed articles, including some papers in renowned journals, such as Hepatology, Cancer research, Oncogene, Cancer letters, etc. and undertaken over 20 national scientific research programs. Dr. Yun also authored book chapters, abstracts and exhibits, and given lectures worldwide. In 2018, he was awarded the leading medical talents of Guangdong Province. In 2019, he was honored with the second prize of National Scientific and Technological Progress Award and Wiley Health Science Researcher Award.

Molecular mechanism in liver cancer development. Prognostic, predictive, and diagnostic markers for GI tumors

For information on Professor Yun's laboratory, click here and select: Mechanisms involved in hepatocarcinogenesis and tumor metastasis.

MD., Hunan Medical University, China, 1980-1985.

MA. in Pathology, Sun Yat-Sen University, China, 1988-1991.

Ph.D in Pathology, The Chinese University of Hong Kong, China, 1998-2001.

1. Chen SL, Liu LL, Wang CH, Lu SX, Yang X, He YF, Zhang CZ, Yun JP*. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways. Mol Oncol 2019 Oct 31.

2. Huang YH, Yan SM, Liu LL, Lu JB, Yang X, He YF, Yun JP*. Incidental lymphoma in lymph node dissection for carcinoma in the abdominopelvic cavity: a single-institution experience. Virchows Arch. 2019 Sep; 475(3).

3. Huang YH，Shi XL, Zhong P,Wang Y, Xiao HL, Zhou XG, Yun JP*. De Novo Testicular Extranodal NK/T-Cell Lymphoma A Clinicopathologic Study of 21 Cases With Review of Additional 18 Cases in the Literature. Virchows Arch.2019 Sep;475(3):365-372

4. Chen SL, Zhang CZ, Liu LL, Lu SX, Pan YH, Wang CH, He YF, Lin CS, Yang X, Xie D, Yun JP*. A GYS2/p53 Negative Feedback Loop Restricts Tumor Growth in HBV-Related Hepatocellular Carcinoma. Cancer Res. 2019 02 01;79(3).

5. Wang H, Zhang CZ, Lu SX, Zhang MF, Liu LL, Luo RZ, Yang X, Wang CH, Chen SL, He YF, Xie D, Xu RH, Yun JP*. A Coiled-Coil Domain Containing 50 Splice Variant Is Modulated by Serine/Arginine-Rich Splicing Factor 3 and Promotes Hepatocellular Carcinoma in Mice by the Ras Signaling Pathway. Hepatology 2019 Jan; 69(1).

6. Zhang CZ, Chen SL,Wang CH,,He YF,Yang X, Xie D, Yun JP*. CBX8 exhibits oncogenic activity via AKT/β-Catenin activation in hepatocellularcarcinoma. Cancer Res. 2018 Jan 1; 78(1):51-63.

7. Chen SL, Liu LL, Lu SX, Luo RZ, Wang CH, Wang H, Cai SH, Yang X, Xie D, Zhang CZ, Yun JP*. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis. Mol Oncol. 2017 Sep; 11(9):1225-1240.

8. Chen SL, Liu LL, Lu SX, Luo RZ, Wang CH, Wang H, Cai SH, Yang X, Xie D, Zhang CZ, Yun JP*. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis. Mol Oncol. 2017 Sep; 11(9):1225-1240.

9. Lu SX, Zhang CZ, Luo RZ, Wang CH, Liu LL, Fu J, Zhang L, Wang H, Xie D, Yun JP*. Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma. Cancer Lett. 2017 Aug 28; 402:71-80.

10. Zhou X, Zhang CZ, Lu SX, Chen GG, Li LZ, Liu LL, Yi C, Fu J, Hu W, Wen JM, Yun JP*. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. Oncogene. 2015 Feb 19; 34(8):965-77.

11. Yi C, Wang Q, Wang L, Huang Y, Li L, Liu L, Zhou X, Xie G, Kang T, Wang H, Zeng M, Ma J, Zeng Y, Yun JP*. MiR-663, a microRNA targeting p21 (WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene 2012; 31:4421-33.

12. Wang CH, Li M, Liu LL, Zhou RY, Fu J, Zhang CZ*, Yun JP*.  LRG1 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Oncotarget. 2015 Dec 8; 6(39):42118-29.

13. Hu W, Lu SX, Li M, Zhang C, Liu LL, Fu J, Jin JT, Luo RZ, Zhang CZ*, Yun JP*. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma. Oncotarget. 2015 Mar 30;6(9):6570-83.

14. Liu LL, Lu SX, Li M, Li LZ, Fu J, Hu W, Yang YZ, Luo RZ, Zhang CZ*, Yun JP*. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget 2014 Jul 15;5(13):5113-24.

15. Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang ZJ, Peng YH, Yang YZ, Yun JP*. miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis 2014;35:469-78.

16. Hu W,Fu J,Lu SX,Liu LL,Luo RZ,Yun JP*,Zhang CZ*. Decrease of Bcl-xL/Bcl-2-associated death promoter in hepatocellular carcinoma indicates poor prognosis. Am J Cancer Res.  2015 Apr 15;5(5):1805-13.

17. Zhang CZ, Fang EF, Zhang HT, Liu LL, Yun JP*. Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma. Invest New Drugs. 2015 Feb;33(1):1-11.

18. Fu J, Li M, Wu DC, Liu LL, Chen SL, Yun JP. Increased Expression of CAP2 Indicates Poor Prognosis in Hepatocellular Carcinoma. Transl Oncol. 2015 Oct;8(5):400-6.

19. Liu LL, Zhang MF, Pan YH, Yun JP*, Zhang CZ*. NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis. Tumour Biol 2014.

20. Fu J, Qiu H, Cai M, Pan Y, Cao Y, Liu L, Yun JP*, Zhang CZ*. Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci 2013;104:508-15.

21. Luo R, Zhang M, Liu L, Lu S, Zhang CZ*, Yun JP*. Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PLoS One 2013;8:e70511.

22. Huang Y, Li LZ, Zhang CZ, Yi C, Liu LL, Zhou X, Xie GB, Cai MY, Li Y, Yun JP*. Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis. J Transl Med 2012;10:106.

23. Cai MY, Luo RZ, Chen JW, Pei XQ, Lu JB, Hou JH, Yun JP*. Overexpression of ZEB2 in peritumoral liver tissue correlates with favorable survival after curative resection of hepatocellular carcinoma. PLoS One 2012;7:e32838.

24. Wang X, Liang Y, Chen Q, Xu HM, Ge N, Luo RZ, Shao JY, He Z, Zeng YX, Kang T, Yun JP*, Xie F*. Prognostic significance of SOX2 expression in nasopharyngeal carcinoma. Cancer Invest 2012;30:79-85.

25. Zhang CZ, Liu L, Cai M, Pan Y, Fu J, Cao Y, Yun JP*. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One 2012;7:e51703.

26. Liu L, Zhang CZ, Cai M, Fu J, Chen GG, Yun JP*. Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One 2012;7:e41293.

27. Zhang CZ, Pan Y, Cao Y, Lai PB, Liu L, Chen GG, Yun JP*. Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo. PLoS One 2012;7:e39870.

28. Li JD, Zhuang Y, Li YF, Feng YL, Hou JH, Chen L, Zhu AN, Wu QL, Yun JP*. A clinicopathological aspect of primary small-cell carcinoma of the uterine cervix: a single-centre study of 25 cases. J Clin Pathol 2011;64:1102-7.

29. He L, Ding H, Wang JH, Zhou Y, Li L, Yu YH, Huang L, Jia WH, Zeng M, Yun JP, Luo RZ, Zheng M. Overexpression of karyopherin 2 in human ovarian malignant germ cell tumor correlates with poor prognosis. PLoS One 2012;7:e42992.

30. Huang L, Zheng M, Zhou QM, Zhang MY, Jia WH, Yun JP*, Wang HY. Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer 2011;117:3363-73.

31. Wang QQ, Zhang ZY, Xiao JY, Yi C, Li LZ, Huang Y, Yun JP*. Knockdown of nucleophosmin induces S-phase arrest in HepG2 cells. Chin J Cancer 2011;30:853-60.

32. Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, Chen JG, Chen YB, Yun JP*, Xia JC. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One 2011; 6: e18219.

Updated May 2020 by International Office, Sun Yat-sen University Cancer Center